Chemo-free approach in acute promyelocytic leukemia (APL) treatment
Francesco Lo Coco
EBMT 2017: Highlighting the hottest topics in the field of transplantation
Transforming healthcare with Twitter: A physician’s perspective
Can 7+3 as induction therapy for acute myeloid leukemia (AML) be optimized?
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?